First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
Bristol-Myers Squibb
Yelena Y Janjigian; Jaffer A Ajani; Markus Moehler; Lin Shen; Marcelo Garrido; Carlos Gallardo; Lucjan Wyrwicz; Kensei Yamaguchi; James M Cleary; Elena Elimova; Michalis Karamouzis; Ricardo Bruges; Tomasz Skoczylas; Arinilda Bragagnoli; Tianshi Liu; Mustapha Tehfe; Thomas Zander; Ruben Kowalyszyn; Roberto Pazo-Cid; Michael Schenker; Kynan Feeny; Rui Wang; Ming Lei; Clara Chen; Raheel Nathani; Kohei Shitara